1. Final Analysis of COVID-19 Patients With Inflammatory Bowel Disease in Japan (J-COSMOS): A Multicenter Registry Cohort Study
- Author
-
Hiroshi Nakase, Yuki Hayashi, Yoshihiro Yokoyama, Takayuki Matsumoto, Minoru Matsuura, Hideki Iijima, Katsuyoshi Matsuoka, Naoki Ohmiya, Shunji Ishihara, Fumihito Hirai, Daiki Abukawa, Tadakazu Hisamatsu, Makoto Sasaki, Masahiro Iizuka, Mikihiro Fujiya, Fukunori Kinjo, Shiro Nakamura, Noriko Kamata, Yuri Etani, Fumiaki Ueno, Sakiko Hiraoka, Takeo Kondo, Takashi Kagaya, Makoto Naganuma, Kiyonori Kobayashi, Taku Kobayashi, Shuji Yamamoto, Yuji Naito, Yoki Furuta, Keichi Mitsuyama, Yu Hashimoto, Katsuhiro Arai, Shingo Kato, Itaru Iwama, Motohiro Esaki, Hiroki Tanaka, Satoshi Motoya, Atsuo Maemoto, Toshifumi Ashida, Nobuaki Nishimata, Shigeaki Aono, Akira Andoh, Hironori Yamamoto, Toshiaki Shimizu, Maeda Yasuharu, Kenji Kinoshita, Katuyuki Fukuda, Jun Kato, Ken Takeuchi, Masakazu Nagahori, Masakatsu Fukuzawa, Masayuki Saruta, Takayoshi Suzuki, Michio Itabashi, Masaru Shinozaki, Soichiro Ishihara, Naoki Yoshimura, Yoichi Kakuta, Kenichi Takahashi, Keiichi Tominaga, Ryosuke Sakemi, Sohachi Nanjo, Shusaku Yoshikawa, Keiji Ozeki, Ayako Fuchigami, Takehiko Katsurada, Kenji Watanabe, Hirotake Sakuraba, Takashi Hisabe, Shigeru Iwase, Ryota Hokari, Katsuhiko Nakai, Takeshi Ueda, Shojiro Yamamoto, Kazutaka Koganei, Reiko Kunisaki, and Akira Hokama
- Subjects
Body Mass Index ,Cerebrovascular Disease ,Corticosteroids ,SARS-CoV-2 ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Background and Aims: Japan has experienced 8 waves of the coronavirus disease 2019 (COVID-19) outbreak over the past 3 years, resulting in an increasing number of deaths and incidence of severe infections. This study aimed to analyze the data from the Japanese inflammatory bowel disease (IBD) patients with COVID-19 registry (J-COSMOS) up to the eighth wave to investigate the clinical course of IBD patients with COVID-19 and factors contributing to disease severity. Methods: In this multicenter, observational, cohort study, we analyzed a cohort of 1308 IBD patients diagnosed with COVID-19, enrolled across 77 participating facilities in the J-COSMOS registry from June 2020 to December 2022. Data on age, sex, IBD (classification, treatment, and activity), and COVID-19 (symptoms, severity, and treatment) were analyzed. Results: The majority of patients (76%) were in clinical remission. According to the World Health Organization classification of COVID-19 severity, 98.4% of IBD patients had nonsevere disease, while 1.6% of patients had severe or critical disease. COVID-19 did not affect disease activity in most IBD patients. Stepwise logistic regression analysis revealed that high body mass index, and cerebrovascular disease were risk factors for severe COVID-19. Corticosteroids could affect COVID-19 severity, whereas anti-tumor necrosis factor α antibodies and thiopurines were associated with a reduced risk of severe COVID-19. No deaths were observed among IBD patients with COVID-19 registered in this cohort. Conclusion: The impact of COVID-19 on IBD disease activity and factors associated with COVID-19 severity were consistent with findings of previous reports. No deaths in Japanese patients with IBD were observed.
- Published
- 2023
- Full Text
- View/download PDF